CN104619334A - 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 - Google Patents

超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Download PDF

Info

Publication number
CN104619334A
CN104619334A CN201380047839.4A CN201380047839A CN104619334A CN 104619334 A CN104619334 A CN 104619334A CN 201380047839 A CN201380047839 A CN 201380047839A CN 104619334 A CN104619334 A CN 104619334A
Authority
CN
China
Prior art keywords
receptor
cytokine
mutein
cells
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047839.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·K·加西亚
D·L·巴特斯
I·莫拉加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN201910717548.0A priority Critical patent/CN110615835A/zh
Publication of CN104619334A publication Critical patent/CN104619334A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380047839.4A 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 Pending CN104619334A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910717548.0A CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261681490P 2012-08-09 2012-08-09
US61/681490 2012-08-09
US201261725791P 2012-11-13 2012-11-13
US61/725791 2012-11-13
US201361825980P 2013-05-21 2013-05-21
US61/825980 2013-05-21
PCT/US2013/054164 WO2014074186A2 (en) 2012-08-09 2013-08-08 Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Division CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Publications (1)

Publication Number Publication Date
CN104619334A true CN104619334A (zh) 2015-05-13

Family

ID=50685291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380047839.4A Pending CN104619334A (zh) 2012-08-09 2013-08-08 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910717548.0A Pending CN110615835A (zh) 2012-08-09 2013-08-08 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法

Country Status (6)

Country Link
US (3) US9738696B2 (enExample)
EP (1) EP2882449B1 (enExample)
JP (2) JP6445434B2 (enExample)
CN (2) CN104619334A (enExample)
IN (1) IN2015KN00329A (enExample)
WO (1) WO2014074186A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190062490A (ko) 2016-09-30 2019-06-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Iii형 변이체 인터페론 및 신테카인
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
EP3802579A1 (en) 2018-06-01 2021-04-14 The Board of Trustees of the Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN114144194B (zh) 2019-04-19 2025-03-14 斯纳凯恩制药私人有限责任公司 一种包含il13的融合蛋白
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4532018A1 (en) * 2022-05-24 2025-04-09 University of Pittsburgh - of the Commonwealth System of Higher Education Interleukin 4 and/or interleukin 13-based eye compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508179A (ja) 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
WO2002018422A1 (en) 2000-08-30 2002-03-07 The Penn State Research Foundation Amino acid substitution mutants of interleukin 13
US6673602B1 (en) 1999-06-11 2004-01-06 The General Hospital Corporation Herpes simplex virus amplicon vector targeting system and method of using same
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
HK1044170B (en) 1999-09-09 2008-08-01 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30. combinations thereof. antibodies. uses in pharmaceutical compositions
WO2001025282A1 (en) 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants
AU1599301A (en) 1999-11-11 2001-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CA2450147A1 (en) 2001-06-07 2002-12-19 Wyeth Solution structure of il-13 and uses thereof
US20040248260A1 (en) 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
EP1846039A2 (en) 2005-01-10 2007-10-24 Research Development Foundation Targeted chimeric molecules for cancer therapy
AU2006347606B2 (en) 2005-09-09 2012-10-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for inhibiting cell death or enhancing cell proliferation
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
BRPI0711965A2 (pt) 2006-06-07 2012-01-24 Genzyme Corporation terapia de gene para esclerose lateral amiotrófica e outras enfermidades da medula espinal
WO2008101671A2 (en) 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
US9155798B2 (en) 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
CA2724630A1 (en) 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
US20110171219A1 (en) 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
US20100183545A1 (en) 2008-10-14 2010-07-22 The United States Of America, As Represented By The Secretary, Targeted cargo protein combination therapy
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
US20110023680A1 (en) 2009-07-30 2011-02-03 Kuo-Chung Wang Pcb cutter module with detachable cutters
TWI397428B (zh) 2009-12-29 2013-06-01 Ind Tech Res Inst 標的第四介白素受體之傳輸系統
WO2011106779A1 (en) 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
US9076405B2 (en) 2010-03-03 2015-07-07 Sharp Kabushiki Kaisha Display device, method for driving same, and liquid crystal display device
US20160354472A1 (en) 2010-10-22 2016-12-08 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
NZ616405A (en) 2011-04-08 2015-11-27 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
WO2012139112A1 (en) 2011-04-08 2012-10-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
WO2013112871A1 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic il-13 polypeptides
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
PL3068797T3 (pl) 2013-11-11 2020-06-29 Wake Forest University Health Sciences Konstrukty wielowalentnego celowania w nowotwory
KR20230004939A (ko) 2014-02-07 2023-01-06 맥마스터 유니버시티 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
KR20170073593A (ko) 2014-09-09 2017-06-28 유넘 테라퓨틱스 키메라 수용체 및 면역 요법에서의 그의 용도
JP6657195B2 (ja) 2014-09-19 2020-03-04 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
WO2016089916A1 (en) 2014-12-02 2016-06-09 Roger Williams Hospital Methods and compositons for treating cancer
BR112018014150A2 (en) 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
WO2018112266A1 (en) 2016-12-14 2018-06-21 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
AU2018347796B2 (en) 2017-10-10 2025-07-24 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
JP2022519377A (ja) 2019-02-07 2022-03-23 メディシナ セラピューティクス インコーポレイテッド がんのバイオマーカーとしてのｉｌ－４ｒ
CN116390744A (zh) 2020-06-24 2023-07-04 梅迪塞纳医疗股份有限公司 双功能性超级因子及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335426B1 (en) * 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BATES D. L. ET AL.: "3QB7：Interleukin-4 mutant RGA bound to cytokine receptor common gamma", 《RCSB PDB》 *
CREUSOT ET AL.: "Engineering cell-type selective immune responses using mechanism-based designer IL-4 cytokines", 《THE JOURNAL OF IMMUNOLOGY》, vol. 186, 31 December 2011 (2011-12-31) *
SCHNARE ET AL.: "Specific Antagonism of Type I IL-4 Receptor with a Mutated Form of Murine IL-4", 《THE JOURNAL OF IMMUNOLOGY》, vol. 161, 31 December 1998 (1998-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110582293A (zh) * 2017-03-31 2019-12-17 小利兰·斯坦福大学托管委员会 合成因子组合物及使用方法
US12540188B2 (en) 2020-08-05 2026-02-03 Synthekine, Inc. IL10Rα/IL2Rγ synthetic cytokines

Also Published As

Publication number Publication date
US12187771B2 (en) 2025-01-07
US20180016316A1 (en) 2018-01-18
EP2882449A4 (en) 2016-03-09
JP2015525574A (ja) 2015-09-07
JP6445434B2 (ja) 2018-12-26
EP2882449A2 (en) 2015-06-17
WO2014074186A3 (en) 2014-06-19
US10738096B2 (en) 2020-08-11
US20160244499A1 (en) 2016-08-25
WO2014074186A2 (en) 2014-05-15
CN110615835A (zh) 2019-12-27
US9738696B2 (en) 2017-08-22
IN2015KN00329A (enExample) 2015-07-10
US20210188932A1 (en) 2021-06-24
JP2018161143A (ja) 2018-10-18
EP2882449B1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
US12187771B2 (en) Method of producing Th9 T-cells
JP7503794B2 (ja) インターロイキン－２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
Bernstein et al. Engineering the IL‐4/IL‐13 axis for targeted immune modulation
JP6441867B2 (ja) インターロイキン２のスーパーアゴニストおよびアンタゴニスト
EP1793856A2 (en) Methods and compositions for treating allergic inflammation
CN110974958B (zh) 一种抗pd-l1单克隆抗体的注射制剂
TWI363091B (en) Uses of mammalian cytokine; related reagents
US20110311475A1 (en) Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants
CN112843222A (zh) Ankrd22蛋白在制备治疗或延缓自身免疫性疾病的产品中的应用
CN114380919A (zh) 经修饰的il-2分子及其用途
CN103382220A (zh) 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用
CN101190944A (zh) 人类新细胞因子及其用途
Zhao et al. Extracellular cyclophilin a binding to CD146 is critical for Th17 cell differentiation in rheumatoid arthritis
CA2946398C (en) Superagonists, partial agonists and antagonists of interleukin-2
Rosenberg et al. Characterization of Lamprey IL-17 Family

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513

RJ01 Rejection of invention patent application after publication